Zeranol

Zeranol

SCHEMBL343987

C[C@H]1CCCC(O)CCCCCc2cc(O)cc(O)c2C(=O)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
ESR2 Q92731 3/20 1.00
ALDH1A1 P00352 3/20 1.00
HSP90AA1 P07900 2/20 1.00
HSP90AB1 P08238 2/20 1.00
NR1I2 O75469 2/20 1.00
CYP3A4 P08684 2/20 1.00
TP53 P04637 1/20 1.00
POLB P06746 1/20 1.00
MAPT P10636 1/20 1.00
ESR1 P03372 2/20 0.61
HPGD P15428 1/20 0.61
STAT3 P40763 1/20 0.61
MKNK2 Q9HBH9 3/20 0.60
MKNK1 Q9BUB5 1/20 0.60
ACVRL1 P37023 4/20 0.59
F13A1 P00488 1/20 0.57
TGM2 P21980 1/20 0.57
KDR P35968 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zeranol SCHEMBL9592548 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Taleranol SCHEMBL29554859 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Taleranol SCHEMBL343276 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL31122084 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL109174 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL10773090 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL29554783 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL2602612 1.00 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL28985464 0.99 LMNA (0.98) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL28584517 0.95 LMNA (0.91) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
US-20230383269-A1 TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF DSM Austria GmbH (AT) 2023-11-30 US disclosed
EP-4225901-A1 TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF DSM Austria GmbH (AT) 2023-08-16 EP disclosed
WO-2022073649-A1 TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF ERBER AKTIENGESELLSCHAFT (AT) 2022-04-14 WO disclosed
CN-114292828-A Tetrameric alpha/beta hydrolase variants with improved temperature stability and methods of use and production thereof 爱尔伯股份公司 2022-04-08 CN disclosed
EP-2292585-B1 Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound APTUIT WEST LAFAYETTE LLC (US) 2016-04-27 EP disclosed
EP-2417118-B1 A PROCESS FOR MANUFACTURING ZERANOL INTERVET INT BV (NL) 2016-01-27 EP disclosed
US-8920559-B2 Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound APTUIT (WEST LAFAYETTE), LLC (US) 2014-12-30 US disclosed
US-8674120-B2 Process for manufacturing zeranol INTERVET INTERNATIONAL B.V. (NL) 2014-03-18 US disclosed
US-8350085-B2 Cocrystallization NEW FORM PHARMACEUTICALS INC. (US) 2013-01-08 US disclosed
WO-2010115478-A1 A PROCESS FOR MANUFACTURING ZERANOL INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed
US-7767708-B2 Growth stimulant compositions SCHERING-PLOUGH ANIMAL HEALTH CORP. (US) 2010-08-03 US disclosed
US-20090281195-A1 NOVEL COCRYSTALLIZATION S.S.C.I., INC. (US) 2009-11-12 US disclosed
US-20090075962-A1 GROWTH STIMULANT COMPOSITIONS SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2009-03-19 US disclosed
US-7452555-B2 Cocrystallization S.S.C.I., INC. (US) 2008-11-18 US disclosed
US-20070287194-A1 Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound S.S.C.I., INC 2007-12-13 US disclosed
US-20070088508-A1 Cocrystallization methods APTUIT (WEST LAFAYETTE), LLC 2007-04-19 US disclosed
WO-2007038524-A2 COCRYSTALLIZATION METHODS SSCI, INC. (US) 2007-04-05 WO disclosed
WO-2000025743-A2 IMPROVED GROWTH STIMULANT COMPOSITIONS SCHERING CORPORATION (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230383269-A1 TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF HDHD5, NCEH1, DNPH1 LMNA 2031/4885SMN1; SMN2 2071/4885ESR2 2799/4885
US-20090075962-A1 GROWTH STIMULANT COMPOSITIONS GHRHR, GHSR, AREG LMNA 2924/4885SMN1; SMN2 2306/4885ESR2 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.